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Abstract
Background: With the aging of the global population, an increasing number of elderly are diagnosed with
advanced non-small cell lung cancer. Although systematic chemotherapy has been one of the primary treatments
for advanced non-small cell lung cancer worldwide, the elderly cannot always tolerate standard platinum-based
doublet chemotherapy, thus resulting in treatment failure. To reduce toxicity, single-agent chemotherapy is often used
to treat the elderly with non-small cell lung cancer; however, this may increase the risk of treatment failure due to an
inadequate dose. It has been shown that compound kushen injection in combination with chemotherapy can enhance
the efficacy and reduce the toxicity. The aim of this trial is to assess the clinical effectiveness and safety of compound
kushen injection in combination with single-agent chemotherapy versus platinum-based doublet chemotherapy in the
treatment of elderly patients with advanced non-small cell lung cancer.
Methods: This multicenter study will be an open-label, randomized controlled trial. Three hundred seventy elderly
patients with advanced non-small cell lung cancer will be randomly divided into experimental (n = 185) and control
groups (n = 185) to receive compound kushen injection in combination with single-agent chemotherapy or standard
platinum-based doublet chemotherapy for two cycles. After two cycles, the disease control rate, objective response
rate, clinical symptoms, quality of life, Karnofsky Performance Status, and side effects will be assessed. Follow-up
evaluations will be performed every 8 weeks to evaluate the progression-free and overall survival.
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Discussion: Before the trial was designed, compound kushen injection was shown to be effective for lung cancer
through basic experiments and clinical trials. This study will determine whether or not the efficacy of compound
kushen injection in combination with single-agent chemotherapy is comparable to that of platinum-based doublet
chemotherapy, and whether or not the toxicity of compound kushen injection in combination with single-agent
chemotherapy is lower than that of platinum-based doublet chemotherapy.
Trial registration: ChiCTR-IPR-14005484 (16 November 2014).
Keywords: Compound kushen injection, Elderly, Non-small cell lung cancer, Single-agent chemotherapy, Study
protocol
Background
The incidence of lung cancer has been increasing rapidly
worldwide. Currently, lung cancer morbidity and mortal-
ity are greater than the morbidity and mortality of other
malignant tumors [1], and lung cancer morbidity and
mortality are closely related to age. According to statis-
tical data from the United States National Cancer Insti-
tute, the morbidity and mortality of patients with lung
cancer who are > 65 years of age are 9.8- and 16.5-fold
greater than those of patients who are < 65 years of age,
respectively [2]. Because aging of the global population
is on the rise, the morbidity and mortality of lung cancer
are also increasing.
Five and 10 years after the diagnosis of lung cancer,
the percent survival for patients < 50 years of age is 16 %
and 10 %, respectively. In contrast, the percent survival
for patients > 70 years of age is 12 % and 5 %, respect-
ively, which means that older people have a lower prob-
ability of surviving lung cancer. Using non-small cell
lung cancer (NSCLC) as an example, which accounts
for > 80 % of all lung cancer pathologies [3], 77.69 % of
patients are > 65 years of age when a definite diagnosis is
established [4]. Over the past 20 years, the mortality of
NSCLC among youth has decreased, but mortality
among the aged is on the rise [5].
In the treatment of patients with advanced NSCLC, sys-
tematic chemotherapy with platinum-based doublets is
considered as standard therapy. Sörenson et al. [6] have
demonstrated that chemotherapy consisting of platinum-
based combinations for patients with advanced NSCLC
can provide a survival advantage over supportive care
alone. However, in addition to aging, elderly patients begin
to deteriorate due to a decline in metabolism and a decay
in organ function, which will result in drug clearance
problems and increased chemotherapy toxicity. Thus,
some older patients with advanced NSCLC cannot toler-
ate the side effects caused by standard chemotherapy [7].
Nevertheless, although single-agent chemotherapy induces
less toxicity compared with doublet chemotherapy, single-
agent chemotherapy will also reduce efficacy and may
result in treatment failure. Delbaldo et al. [8] conducted a
meta-analysis that pooled 65 trials (n = 13,601 patients).
Specifically, comparing a doublet regimen with a single-
agent regimen, a significant decrease was noted in tumor
response (OR = 0.42, 95 % CI = 0.37–0.47, P < 0.001) and
1-year survival (OR = 0.80, 95 % CI = 0.70–0.91, P < 0.001)
in favor of the single-agent regimen. Therefore, an effect-
ive therapy with low toxicity is urgently needed for the
elderly with advanced lung cancer.
Integrated traditional Chinese and Western medicine
therapy have been the most distinctive methods in the
treatment of malignant tumors in China. In the treatment
of NSCLC, traditional Chinese medicine (TCM) in com-
bination with chemotherapy can enhance the efficacy and
reduce chemotherapy-induced toxicity [9, 10]. As a repre-
sentative of TCM injection, compound kushen injection
(CKI) has good effects on pain relief, ensuring hemostasis,
anti-inflammatory activity, and anti-fibrosis [11]. CKI also
has efficacy in the treatment of lung cancer [12]. When
combined with chemotherapy, CKI enhances efficacy,
reduces toxicity, and protects organs to improve the
quality of life (QoL) and help patients complete
chemotherapy [13, 14]. When considering elderly pa-
tients’ characteristics, the side effects of traditional
chemotherapy, and the unique function of CKI, treat-
ment with CKI in combination with single-agent
chemotherapy could be more reasonable and effective
for the elderly with advanced lung cancer compared to
standard chemotherapy.
Currently, large-scale clinical trials always exclude
elderly patients with lung cancer [15]. As a result, there
is little high-level or large-scale evidence from evidence-
based medicine with a focus on the elderly with lung
cancer [16]. Therefore, there is an urgent need to find a
new effective therapy with less toxicity for the elderly
with lung cancer. To evaluate the efficacy and safety of
CKI in combination with single-agent chemotherapy for
the elderly with advanced NSCLC, a multicenter, ran-
domized, controlled, open-label trial has been designed
with disease control rate (DCR) as the main observation
index. A novel therapy for the elderly with advanced
lung cancer is expected.
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Methods/design
Study design
This is a multicenter, randomized, controlled, open-label
phase IV trial. Guang’anmen Hospital of the China
Academy of Chinese Medical Sciences, TCM Hospital of
Shanxi Province, TCM Hospital of Zhejiang Province,
Anhui Provincial Hospital, and Tongde Hospital of
Zhejiang Province will participate in this study. The in-
cluded subjects (n = 370) will be randomly divided into
experimental (n = 185) and control groups (n = 185)
according to a random number table, which is gener-
ated by SAS 9.3. Both groups will undergo two treat-
ment cycles with 21 days per cycle. The treatment
course may extend to 28 days a cycle if necessary. The pri-
mary and secondary aims will be assessed after two cycles.
After two cycles, follow-up evaluations will be performed
every 8 weeks until death occurs. In addition, the block
size and treatment assignment table will not be available
to the investigators until the end of the study (Fig. 1).
Eligibility criteria
Eligible patients will be those who meet all of the follow-
ing inclusion criteria and who have none of the listed
exclusion criteria.
Diagnostic criteria
The diagnostic criteria and TNM classification of NSCLC
in this study refer to “Chinese common malignant tumor
diagnosis and treatment norm—lung cancer diagnostic
criteria,” as promulgated by the Ministry of Health of the
People’s Republic of China.
Inclusion criteria
The inclusion criteria were as follows:
(1)Before the start of the study, patient fully
understands the study and is willing to sign the
informed consent form;
(2)65–75 years of age without gender restriction;
(3)Histologic or cytologic confirmation of III-IV stage
NSCLC;
(4)According to RECIST (version 1.1), there should be at
least one measurable lesion without local treatment,
and the maximum diameter should be > 10 mm (the
shortest diameter of malignant lymph nodes should
be > 15 mm) by spiral CT or MRI;
(5)Eastern Cooperative Oncology Group (ECOG)
performance status less than at least 2 points;
(6)The last radiotherapy or chemotherapy session
should be > 4 weeks;
(7)White blood cell (WBC) count > 3.0 × 109/L,
neutrophil count > 1.5 × 109/L, platelet (PLT)
count > 60 × 109/L, hemoglobin (Hb) > 8.0 g/dl, total
bilirubin (TBIL) within the normal range or < 1.5 ×
the upper limit of normal (ULN), either aspartate
transaminase (AST [SGOT]) or alanine
transaminase (ALT [SGPT]) < 2.0 × ULN); and
serum creatinine (SCr) < 1.5 × ULN;
(8)Expected survival > 3 months.
Exclusion criteria
The exclusion criteria were as follows:
(1)CKI within 2 weeks;
Fig. 1 Flow diagram of the trial
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(2)Only immeasurable lesions, such as pleural
effusions, pulmonary lymphangitic carcinomatosis,
ascites, peritoneal cancer lesions, diffuse hepatic
involvement, and bone metastases;
(3)Severe, uncontrolled organic lesions or infections,
such as decompensated heart, lung, and kidney
functional failure, leading to intolerance of
chemotherapy;
(4)Current participation in another clinical study or
participation in another clinical study within
30 days;
(5)Pregnant or lactating women;
(6)Allergy to the test drug.
Recruitment
Recruitment began in November 2014 and is expected to
end in May 2016. Within 18 months after beginning the
trial, patients will be screened according to the inclusion
and exclusion criteria to identify eligible participants. This
trial will be designed in accordance with the principle of
protecting patient rights and interests, and carried out in
accordance with the Declaration of Helsinki (version 8),
Good Manufacturing Practice (GMP) guidelines, and the
2007 Biological Ethics Review Method Involving Humans
by the Ministry of Health of the People’s Republic of
China. Written informed consent will be obtained from all
patients before participation in the trial.
Study aims
The primary aim of this study will be to observe whether
or not CKI in combination with single-agent chemother-
apy has a similar or better effect on improving the DCR
and objective response rate (ORR) in elderly patients
with advanced NSCLC versus platinum-based doublet
chemotherapy. The secondary aims of our trial will be to
compare progression-free survival (PFS), overall survival
(OS), clinical symptoms, quality of life (QoL), Karnofsky
Performance Status (KPS), and adverse drug reactions
(ADRs) between the two groups.
Sample size
This trial will be a non-inferiority trial, in which the
primary endpoint will be DCR. Schiller et al. [17] com-
pared four chemotherapy regimens (cisplatin and pacli-
taxel, cisplatin and gemcitabine, cisplatin and docetaxel,
and carboplatin and paclitaxel) for advanced NSCLC, in
which the DCRs were 51 %, 60 %, 58 %, and 51 %,
respectively. It is assumed that 60 % of DCRs in each
treatment arm will respond to treatment within two
cycles. A non-inferiority margin of 15 % and a one-sided
type I error of 2.5 % ensured 80 % power to demonstrate
non-inferiority of CKI in combination with single-agent
chemotherapy versus platinum-based doublet chemo-
therapy. Allowing for approximately 10 % of patients to
be excluded from the population, an enrollment of 370
patients (that is, 185 patients per treatment arm) is
planned.
Recruitment
The standard of care for the first-line treatment of
advanced NSCLC remains the use of platinum-based
doublets (GP, TP, or DP) in patients with good perform-
ance status and no significant comorbidities [18, 19]. In
this trial, the DCR will serve as the primary outcome.
The GP, TP, and DP regimens, which are the third-
generation cytotoxic agents, have similar DCR effects on
advanced NSCLC [17, 19]. Consequently, the three chemo-
therapy regimens were permitted to be administered at the
same time. Considering the physiologic characteristics of
the elderly, if the efficacy of CKI in combination with
single-agent chemotherapy on elderly patients with
advanced NSCLC is not inferior to platinum-based doublet
chemotherapy, the long-term effects or side effects of
chemotherapy are not excessive, and compound therapy is
superior to platinum-based doublet chemotherapy, it seems
reasonable to treat the elderly with advanced NSCLC using
this therapeutic method.
Randomization
Randomized sequences will be generated by the contract
research organization (CRO), Da Wei Asian Pharmaceut-
ical Technology (Beijing) Co., Ltd., as the third party. SAS
9.3 software will be used to generate a random sequence
table for the subjects. Three hundred seventy random
numbers and the allocation sequence table of the random-
ized group will be kept as blind codes. The subjects will
be randomly divided into the experimental (n = 185) and
control (n = 185) groups at a ratio of 1:1.
Allocation concealment
According to the randomized sequences, the third party
will place paper strips with black characters on a gray
background into non-transparent envelopes, which will
be sealed with adhesive tape.
Intervention
Patients in the experimental group will receive mainline
treatments of 250 ml of CKI (20 ml diluted in 0.9 % nor-
mal saline [0.9 % NS]), and 14 days of continuous and
once daily use, which will be accompanied by single-agent
chemotherapy (gemcitabine, paclitaxel, or docetaxel).
Patients in the control group will receive mainline
treatments of platinum-based doublet chemotherapy
(GP, TP, or DP). The three regimens have no statisti-
cally significant difference in the response rates, PFS,
and OS [16]. A chemotherapy cycle is 21 or 28 days in
length. The outcomes will be assessed after two cycles;
then the follow-up evaluations begin. CKI (specifications:
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5 ml/tube) is produced by Shanxi Zhendong Pharmaceut-
ical Co., Ltd. (Shanxi China). All chemotherapy usage will
be in accordance with the National Comprehensive
Cancer Network (NCCN) guidelines (Table 1).
Withdrawal conditions
Termination by researchers
Study participants may be withdrawn from the study by
the researchers for the following reasons: 1) some compli-
cations and special physiologic changes may occur in
subjects who are not suitable for treatment without a
break; 2) disease progression is confirmed by iconography
and clinical evidence; and 3) serious ADRs may occur.
Termination by subjects
According to the informed consent form, the subjects have
the right to withdraw from the trial. Subjects who do not
accept treatment or re-examinations will be withdrawn.
The reasons for withdrawal will be specified and recorded.
Standards for discontinued testing
The following standards for discontinued testing will be
applied: 1) a serious safety problem occurs; 2) major
mistakes are found in the designed clinical protocol
during the trial; and 3) the sponsor of this trial requests
discontinued testing because of a lack of funds or poor
management.
The withdrawal conditions should be recorded in detail
for further analysis after completion of the study.
Outcome measures and definitions
Primary outcome measures
DCR and ORR will be our primary outcome measures.
Complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD) were defined
according to the Response Evaluation Criteria in Solid
Tumors (RECIST), as developed by the World Health
Organization [20]. CR is defined as the disappearance of
all target lesions and no new lesions. PR is defined as at
least a 30 % decrease in the sum of the longest diameter
of the measurable lesions. PD is defined as at least a
20 % increase in the sum of the longest diameter of the
measurable lesions. SD is defined as small changes
between PR and PD. DCR is the summed percentage of
CR, PR, and SD in all cases, and ORR is the summed
percentage of CR and PR.
Secondary outcome measures
PFS refers to the interval of time from the beginning of
the study to disease progression for the first time or
patient death.
OS indicates the interval of time from the first date of
medication to death for any reason.
Clinical symptoms refer to application of the M.D.
Anderson Symptom Assessment Inventory [21] with 10
additional TCM items (MDASI-TCM), and it has been
shown that this method of questionnaire is a reliable,
valid, sensitive instrument for evaluating the TCM
symptoms of cancer [22]. The newly added items of
TCM symptoms include cough, expectoration, palpita-
tion, sweating, bitter taste, oral ulcers, diarrhea, consti-
pation, dysphoria, and feverish palms and soles. Each
symptom is graded from 0–10 according to patient
symptom severity, where 0 indicates no symptoms and
10 indicates the most severe level of symptoms that a
patient can imagine.
QoL refers to application of the QoL scale (EORTC
QLQ-C30, Chinese version) to evaluate the impact of
drugs on patients with advanced NSCLC [23]. EORTC
QLQ-C30 is the core scale, and includes 30 items. The
method of usage is as follows: the 29th and 30th items
are divided into 7 grades. According to patient answers,
the items are recorded from 1–7 points. Other items are
divided into 4 grades, which are recorded from 1–4
points. For application and statistical analysis, the 30
items of EORTC QLQ-C30 (Table 2) are divided into 15
domains, including 5 functional domains, 3 symptomatic
domains, 1 life-quality domain, and 6 single items (each
one acts as a domain). The Raw Score (RS) in every
domain is the average score of all items in the domain,
according to the following formula: RS = (Q1 +Q2 + „„ +
Qn)/n (Table 3). To compare the scores in every field with
each other, we will use the range method of linear trans-
formation to transform RS into the standard score (SS),
which is obtained from 0–100. Specifically, the calculation
formula areas are as follows (R stands for the score range):
① functional domain, SS = [1-(RS-1)/R] × 100; ② symp-
tomatic and life-quality domains, SS = [(RS-1)/R] × 100.
Table 1 Chemotherapy regimens for NSCLC




Carboplatin AUC = 5–6 D1
GP:
Gemcitabine 1,250 D1, D8
Cis-platinum 75 D1




Carboplatin AUC = 5–6 D1
Notes: The dosage of chemotherapy regimens are only for reference, and
specific implementation will take clinical application as a standard
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The KPS scale refers to the evaluation of a patient’s per-
formance capacity. From another perspective, the KPS scale
can assess a patient’s physical condition. The KPS scale is
calculated for a total of 100 points, which are partitioned
into 10-point increments according to the state of the
illness, degree of independent living, and whether or not
the patient can perform normal activities. A score of 100
points is consistent with good physical condition without
symptoms, 60 points indicates basic self-reliance not
requiring assistance, and 0 points is indicative of death [24].
Table 2 EORTC QLQ-C30
Questions Not at all A little Quite a bit Very much
1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping
bag or a suitcase?
1 2 3 4
2. Do you have any trouble taking a long walk? 1 2 3 4
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4
4. Do you need to stay in bed or a chair during the day? 1 2 3 4
5. Do you need help with eating, dressing, washing yourself, or using the toilet? 1 2 3 4
During the past week:
6. Were you limited in doing either your work or other daily activities? 1 2 3 4
7. Were you limited in pursuing your hobbies or other leisure time activities? 1 2 3 4
8. Were you short of breath? 1 2 3 4
9. Have you had pain? 1 2 3 4
10. Did you need to rest? 1 2 3 4
11. Have you had trouble sleeping? 1 2 3 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked appetite? 1 2 3 4
14. Have you felt nauseated? 1 2 3 4
15. Have you vomited? 1 2 3 4
16. Have you been constipated? 1 2 3 4
During the past week:
17. Have you had diarrhea? 1 2 3 4
18. Were you tired? 1 2 3 4
19. Did pain interfere with your daily activities? 1 2 3 4
20. Have you had difficulty in concentrating on things, like reading a newspaper or
watching television?
1 2 3 4
21. Did you feel tense? 1 2 3 4
22. Did you worry? 1 2 3 4
23. Did you feel irritable? 1 2 3 4
24. Did you feel depressed? 1 2 3 4
25. Have you had difficulty remembering things? 1 2 3 4
26. Has your physical condition or medical treatment interfered with your family life? 1 2 3 4
27. Has your physical condition or medical treatment interfered with your social activities? 1 2 3 4
28. Has your physical condition or medical treatment caused you financial difficulties? 1 2 3 4
For the following questions please circle the number between 1 and 7 that best
applies to you.
29. How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
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Safety assessment
The safety assessment is based on version 3.0 of the
Common Terminology Criteria for Adverse Events
(CTCAE) issued by the National Cancer Institute (NCI)
[25]. Liver and kidney function, routine blood, urine,
and stool testing, and an electrocardiogram will be
inspected to assess drug toxicity and adverse reactions
of the two groups.
Adverse events
According to the CTCAE issued by the NCI, all adverse
events (AEs) must be evaluated objectively. If there are pa-
tients who enroll in the study and discontinue the study
within 30 days due to the emergence of acute and tardive
AEs, the details must be recorded and reported. All the
AEs after starting the trial should be followed until
satisfactory resolution, or the primary researcher should
determine if the AEs have stabilized. The relationship
between the AE and investigational drugs should be
assessed using Table 4 from Measures for the Reporting
and Monitoring of Adverse Drug Reactions, which is issued
by the 2011 Ministry of Health of the People’s Republic of
China (Table 4).
Serious AEs
If serious AEs occur, including hospitalization, prolonged
hospitalization, disability, affect on the ability to work, life
endangerment, or death, corresponding countermeasures
will be conducted by researchers according to the drug-
induced symptoms to ensure patient safety. The results of
treatment will be communicated to the project director,
the Ethics Committee of Guang’anmen Hospital, and the
sponsor of Shanxi Zhendong Pharmaceutical Co., Ltd.
Data management
According to the subjects’ original observation records,
the data will be recorded in a timely and accurate man-
ner into case report forms (CRFs). Supervisors will in-
spect whether or not the study is carried out as the trial
protocol. The CRFs inspected by supervisors will be sent
to the data managers after the supervisor’s signature is
obtained. Before logging, data managers will check the
data again. If problems are found, the supervisor will be
informed in a timely manner and the researcher will be
asked for the reasons. Data entry clerks will double-
enter the data. If any problems exist during the entering
Table 3 Calculation method for each domain in QLQ-C30 (V3.0)
Field Code Character Item amount Scores (R) Calculation method
Physical function PF Function 5 3 (Q1 + Q2 + Q3 + Q4 + Q5)/5
Role function RF Function 2 3 (Q6 + Q7)/2
Emotional function EF Function 4 3 (Q21 + Q22 + Q23 + Q24)/4
Cognitive function CF Function 2 3 (Q20+ Q25)/2
Social function SF Function 2 3 (Q26 + Q27)/2
Global QOL QL 2 6 (Q29 + Q30)/2
Fatigue FA Symptom 3 3 (Q10 + Q12 + Q26)/3
Nausea and vomiting NV Symptom 2 3 (Q14 + Q15)/2
Pain PA Symptom 2 3 (Q9 + Q19)/2
Dyspnea DY Symptom 1 3 Q8
Sleep disturbance SL Symptom 1 3 Q11
Appetite loss AP Symptom 1 3 Q13
Constipation CO Symptom 1 3 Q16
Diarrhea DI Symptom 1 3 Q17
Financial difficulties FI Symptom 1 3 Q28
Table 4 Relevance evaluation standard between AE and
investigational drugs
Judgment results Judgment Index
① ② ③ ④ ⑤
Definite relevance + + – + +
Probable relevance + + – + ?
Difficult to determine + + ± ± ?
Probable irrelevance + – ± ± ?
Definite irrelevance – – + – –
AE Judgment Index: ① Whether or not there is a successive relationship
between time of treatment onset and time of AE occurrence. ② Whether
or not suspicious AE is in accordance with the known AE of the medicine.
③ Whether or not the suspicious AE can be explained by the effect of
combination of medicine, patient’s clinical condition, or other therapies.
④ Whether or not suspicious AE disappears or is relieved after drug
withdrawal or dosage reduction. ⑤ Whether or not similar reactions occur
after using the suspicious drugs again
+ means affirmative, –means negative, ± means difficult to determine, ?
means unclear situation
1- Definite relevance, 2-Probable relevance, 3-Difficult to determine, 4-Probable
irrelevance, 5-Definite irrelevance
The incidence of ADR is calculated by using the sum of the cases of 1 + 2 + 3
as numerator, and the number of all cases as denominator
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procedure, data entry clerks will take the registration
and make a report to handle the problem rapidly. Some
of the CRFs will be selectively checked after data entry
to ascertain the quality of the entry.
The range and logic of data checking will be mapped
out according to the range of the index value and the
relationship by data managers and primary researchers.
The database will be built. The fault data will be con-
trolled before data entry, and the reasons for fault data
will be identified and corrected. Fault content and modi-
fied results will be recorded and properly preserved.
CRFs will be archived in accordance with the order of
the sequence number after data entry and checked. The
information will be safely stored to avoid staining, water
damage, and crimping. The prescribed period of keeping
original files will be in accordance with Standardizing
the quality management of a drug clinical trial.
Statistical analysis
SAS statistical software will be used for statistical ana-
lysis of the collected data. All of the statistical tests will
adopt a two-tailed test, and a significance level of 5 %
will be used throughout the analysis.
All of the measurement data for the two groups will
undergo descriptive statistics. Both two-sample t-tests
and Wilcoxon rank sum tests for continuous data and
chi-squared tests or Fisher’s exact tests for categorical
data will be used to analyze the baseline characteristics.
Paired t-tests will be used to compare intra-group differ-
ences before and after treatment, and variance analysis
will be used to compare inter-group data. Kaplan-Meier
survival analysis will be used to compare the PFS and
OS between the two groups. Log-rank and Cox regres-
sion analyses will also be used. For the primary outcome,
chi-squared tests will be used to compare the DCRs
between the two groups.
Recruitment
With respect to shedding analyses, chi-squared tests will
be used to compare the total shedding rates, including
shedding caused by AEs. Regarding efficiency analyses, the
primary and secondary indices were analyzed by full
analysis set (FAS) and per protocol set (PPS). Because this
study is a multicenter clinical trial, the center effect on the
indices should be considered. With respect to the safety
analysis, chi-squared tests will be used to compare the
incidence of AEs, which will be described by tabulation.
The laboratory results of changes in testing before and
after the trial, and the relationship between the anomaly
index and the investigational drugs will be analyzed.
Ethics
This trial has been reviewed and approved by the Ethics
Committee of Guang’anmen Hospital affiliated with the
China Academy of Chinese Medical Sciences (approval
number: 2014EC086-01). The trial has been registered in
the Chinese Clinical Trial Registry (registration number:
ChiCTR-IPR-14005484).
Discussion
CKI, known as the Yanshu injection, is extracted from two
Chinese herbs (kushen [Radix Sophorae flavescentis] and
baituling [Rhizoma smilacis glabrae]), consisting of the
primary components oxymatrine and matrine [26]. From
the perspective of basic experiments, CKI has been shown
to be effective in the treatment of cancer with or without
combination chemotherapy. Zhang et al. [27] and Xu et al.
[28], using cancer stem cells, performed experiments in
vitro to prove that oxymatrine can directly kill tumor cells
and inhibit their proliferation. Li et al. [29], using oxyma-
trine in combination with chemotherapy, showed that
CKI can increase the sensitivity of chemotherapy to kill
tumor cells effectively. In addition, Zhao et al. [30] found
that CKI blocks TRPV1 signaling and prohibits tumor
growth to relieve cancer pain, then improves the patients’
QoL.
Clinically, the positive benefits of CKI in the treatment
of lung cancer have also been demonstrated [31]. In the
treatment of elderly patients with advanced NSCLC, CKI
has been widely used clinically because of its high effi-
ciency and low toxicity. Lu et al. [32] performed a system-
atic review on CKI adjuvant chemotherapy in the
treatment of lung cancer. The review involved 23 RCTs
(1,750 cases). The results showed that the tumor objective
response rate (OR = 1.68, 95 % CI = 1.32–2.04, P < 0.0001)
and QoL (OR = 2.69, 95 % CI = 1.97–3.68, P < 0.00001) in
patients who received CKI adjuvant chemotherapy and
chemotherapy alone favored the former. CKI has been
shown to be a safe drug. Additionally, Qin [33] enrolled
86 elderly patients who were randomly divided into an
experimental group (n = 43), who received CKI in combin-
ation with chemotherapy (docetaxel with carboplatin),
and a control group (n = 43), who received the docetaxel
with carboplatin chemotherapy alone. Though no statisti-
cally significant difference existed between the two groups
in efficacy (55.81 % versus 53.49 %, P > 0.05), the incidence
of adverse reactions, including nausea and vomiting,
fatigue, constipation, and arrest of bone marrow, was
lower in the experimental group than in the control group
(P < 0.05). The above-mentioned studies could provide
evidence for the feasibility of this trial.
The ages of the targets in this trial will be > 65 years,
in accordance with the definition of the elderly issued by
WHO and the Chinese constitution. Patients > 75 years
of age may not tolerate platinum-based doublet chemo-
therapy and may violate medical ethics. Therefore, the
ages of the targets will be < 75 years.
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There are still some limitations and shortcomings in the
trial design. First, the chemotherapy regimens are different.
Although many studies have demonstrated that these
chemotherapy regimens have similar efficacy in patients
with NSCLC [17, 19], the ADRs of these regimens are
different. Thus, when performing the statistics for the
ADRs at the end of the trial, a hierarchical analysis will be
performed according to the different chemotherapy regi-
mens. In the future, we will redesign a single-regimen
study based on the results of this trial. Second, classifica-
tion of NSCLC pathologic type is not further analyzed.
Third, the requirement on the ages means this trial cannot
cover elderly patients > 75 years of age. Consequently, in
the future we need to conduct the study further based on
what we obtain from this designed trial to clarify the range
of this method and to redesign a new trial for use in the
elderly > 75 years of age.
This paper summarized the methodology for a multi-
center, randomized, controlled, open-label study of CKI in
combination with single-agent chemotherapy in elderly
patients with advanced NSCLC that refers to the CON-
SORT statement [34]. The results of this study will
support and provide parameters for a novel therapy (CKI
in combination with single-agent chemotherapy) used in
the treatment of elderly patients with advanced NSCLC.
Trial status
The trial is currently open to recruitment.
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